The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 06, 2018

Filed:

Apr. 15, 2016
Applicants:

Curis, Inc., Lexington, MA (US);

Genentech, Inc., South San Francisco, CA (US);

Inventors:

Frederic J. de Sauvage, Foster City, CA (US);

Gerrit J. P. Dijkgraaf, San Francisco, CA (US);

Thomas Januario, San Francisco, CA (US);

Robert L. Yauch, Redwood City, CA (US);

Assignees:

Genentech, Inc., South San Francisco, CA (US);

Curis, Inc., Lexington, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/705 (2006.01); C07K 16/28 (2006.01); G01N 33/15 (2006.01); G01N 33/50 (2006.01); G01N 33/74 (2006.01);
U.S. Cl.
CPC ...
G01N 33/74 (2013.01); C07K 14/705 (2013.01); G01N 2333/726 (2013.01); G01N 2500/10 (2013.01);
Abstract

The emergence of mutations in tyrosine kinases following treatment of cancer patients with molecular-targeted therapy represents a major mechanism of acquired drug resistance. Here, we describe a mutation in the serpentine receptor, Smoothened (SMO), which results in resistance to a Hedgehog (Hh) pathway inhibitor in medulloblastoma. A single amino acid substitution in a conserved aspartic acid residue of SMO maintains Hh signaling, but results in the inability of the Hh pathway inhibitor, GDC-0449, to bind SMO and suppress the pathway. This mutation was not only acquired in a GDC-0449-resistant mouse model of medulloblastoma, but was identified in a Medulloblastoma patient following relapse on GDC-0449. The invention provides screening methods to detect SMO mutations and methods to screen for drugs that specifically modulate mutant SMO exhibiting drug resistance.


Find Patent Forward Citations

Loading…